Decoding Cancer
97% of Oncology Drugs Fail. We're Fixing the Model.
Preclinical success on artificial models isn't success—it's a delayed failure. We give your pipeline the biological truth it needs to reach patients.
From Biological Complexity to Clinical Certainty.
Our Organoid 2.0 (ALI-PDO™) technology is the first to preserve the native tumor microenvironment in a scalable format, revealing how a drug truly behaves in a patient.
The genetic blueprint doesn't guarantee the biological outcome. For decades, preclinical models have failed to capture the intricate reality of human tumors, leading to a 97% clinical trial failure rate in oncology. We are changing that. Our Organoid 2.0 (ALI-PDO™) technology is the first to preserve the native tumor microenvironment (TME)—including stromal and immune cells—in a high-throughput, scalable format. This living, functional model of human biology allows us to see what others can't: how a drug truly behaves in a patient.
KEY METRICS
84.43%Clinical Outcome Prediction AccuracyBased on a retrospective analysis of 152 patient cases across 5 solid tumor types (NSCLC, CRC, Breast, Gastric, Pancreatic), comparing ALI-PDO™ drug sensitivity results with actual patient clinical outcomes.
1,500+Patient-Derived Organoid ModelsOur biobank includes 1,500+ PDO models spanning 20+ cancer types, with full genomic and clinical annotation.
20+Solid Tumor Types CoveredIncluding HCC, CRC, NSCLC, Gastric, Breast, Ovarian, Pancreatic, RCC, GBM, Biliary Tract, Head & Neck, Prostate, GIST, Osteosarcoma, and more.
2-3 WeeksStandard Study TurnaroundFrom sample receipt to final report. Feasibility studies in as little as 4 weeks.
One Platform. Every Oncology Challenge.
For I-O Programs
Test your immunotherapy in a model that actually has an immune system.
Explore I-O CapabilitiesFor Biotech Partners
From co-discovery to co-development—we build the science together.
Explore PartnershipsTrusted by Global Leaders in Drug Development.
*Logos displayed with permission. Partner names used for reference only.